Stryker’s second quarter results met Wall Street’s revenue expectations, yet the market responded negatively, reflecting investor concerns about the company’...
Stryker (NYSE:SYK) reported 9% organic sales growth in the second quarter of 2026 and adjusted earnings per share growth of 17.9%, as the medical technology company continued recovering from a cybersecurity incident that disrupted operations earlier in the year.
Chair and CEO Kevin Lobo said the co
What Happened? Shares of medical technology company Stryker (NYSE:SYK) fell 7.3% in the morning session after the company reported second-quarter results tha...
Medical technology company Stryker (NYSE:SYK) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 9.4% year on year to $6.59 billion. Its non-...
Medical technology company Stryker (NYSE:SYK) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 9.4% year on year to $6.59 billion. Its non-...
Medical technology company Stryker (NYSE:SYK) will be reporting earnings this Thursday afternoon. Here’s what investors should know. Stryker missed analysts’...
Stryker (NYSE:SYK) has outperformed the market over the past 20 years by 1.04% on an annualized basis producing an average annual return of 10.3%. Currently, Stryker has a market capitalization of $122.02 billion.
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...
Stryker (NYSE:SYK) has outperformed the market over the past 20 years by 1.17% on an annualized basis producing an average annual return of 10.45%. Currently, Stryker has a market capitalization of $120.58 billion.
